Chromosomal instability determines taxane response

Proceedings of the National Academy of Sciences of the Unite 106, 8671-8676

DOI: 10.1073/pnas.0811835106

Citation Report

#	Article	IF	CITATIONS
1	Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19108-19113.	3.3	274
2	Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncology, 2009, 5, 1363-1370.	1.1	23
3	Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle, 2009, 8, 3262-3266.	1.3	101
4	Taxane pathway. Pharmacogenetics and Genomics, 2009, 19, 979-983.	0.7	43
5	Mechanisms of Chromosomal Instability. Current Biology, 2010, 20, R285-R295.	1.8	480
6	Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Current Opinion in Cell Biology, 2010, 22, 809-815.	2.6	99
7	DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis, 2010, 51, 897-908.	0.9	24
8	Targeting chromosomal instability and tumour heterogeneity in HER2â€positive breast cancer. Journal of Cellular Biochemistry, 2010, 111, 782-790.	1.2	44
9	p53 suppresses structural chromosome instability after mitotic arrest in human cells. Oncogene, 2010, 29, 1929-1940.	2.6	34
10	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene, 2010, 29, 4905-4913.	2.6	153
11	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 2010, 103, 1139-1143.	2.9	381
12	Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nature Reviews Cancer, 2010, 10, 102-115.	12.8	377
13	Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews Drug Discovery, 2010, 9, 790-803.	21.5	1,431
14	From genomic landscapes to personalized cancer management—is there a roadmap?. Annals of the New York Academy of Sciences, 2010, 1210, 34-44.	1.8	16
15	Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature Reviews Clinical Oncology, 2010, 7, 575-582.	12.5	95
16	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177.	1.3	71
17	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365.	5.1	116
18	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2010, 2, 53.	3.6	43

#	ARTICLE	IF	CITATIONS
19	Genomic instability and copyâ€number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Molecular Oncology, 2011, 5, 48-60.	2.1	21
21	The origins of cancer robustness and evolvability. Integrative Biology (United Kingdom), 2011, 3, 17-30.	0.6	144
23	pRB, a tumor suppressor with a stabilizing presence. Trends in Cell Biology, 2011, 21, 433-441.	3.6	75
24	Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Research and Treatment, 2011, 130, 993-1002.	1.1	59
25	Chromosomes and cancer cells. Chromosome Research, 2011, 19, 433-444.	1.0	124
26	Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Medical Genomics, 2011, 4, 18.	0.7	22
27	How Mitotic Errors Contribute to Karyotypic Diversity in Cancer. Advances in Cancer Research, 2011, 112, 43-75.	1.9	46
28	Chromosomal Instability Confers Intrinsic Multidrug Resistance. Cancer Research, 2011, 71, 1858-1870.	0.4	391
29	High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint. Carcinogenesis, 2011, 32, 305-311.	1.3	14
30	Targeting aneuploid cancer cells. Expert Opinion on Therapeutic Targets, 2011, 15, 595-608.	1.5	15
31	TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1959-1967.	1.9	79
32	Targeting the epigenome in ovarian cancer. Future Oncology, 2012, 8, 151-164.	1.1	15
33	Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. Frontiers in Oncology, 2012, 2, 49.	1.3	22
34	Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. International Journal of Oncology, 2012, 41, 1837-1843.	1.4	6
35	Effect of Epothilone B on Cell Cycle, Metabolic Activity, and Apoptosis Induction on Human Epithelial Cancer Cells—Under Special Attention of Combined Treatment with Ionizing Radiation. Cancer Investigation, 2012, 30, 593-603.	0.6	1
36	Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clinical Cancer Research, 2012, 18, 5806-5815.	3.2	150
37	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. Clinical Cancer Research, 2012, 18, 1506-1512.	3.2	217
38	β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Molecular Cancer, 2012, 11, 36.	7.9	51

#	Article	IF	CITATIONS
39	A Screen for Selective Killing of Cells with Chromosomal Instability Induced by a Spindle Checkpoint Defect. PLoS ONE, 2012, 7, e47447.	1.1	15
40	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	2.1	48
41	Losing balance: the origin and impact of aneuploidy in cancer. EMBO Reports, 2012, 13, 501-514.	2.0	239
42	Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Reports, 2012, 13, 528-538.	2.0	332
43	Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. British Journal of Cancer, 2012, 107, 71-74.	2.9	27
44	RB: mitotic implications of a tumour suppressor. Nature Reviews Cancer, 2012, 12, 220-226.	12.8	135
45	Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. Biochemical Pharmacology, 2012, 83, 1013-1020.	2.0	59
46	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. American Journal of Hematology, 2012, 87, 37-41.	2.0	24
47	Radiosensitizing effect of epothiloneÂB on human epithelial cancer cells. Strahlentherapie Und Onkologie, 2012, 188, 177-184.	1.0	13
48	A new assay for measuring chromosome instability (CIN) and identification of drugs that elevate CIN in cancer cells. BMC Cancer, 2013, 13, 252.	1.1	34
49	Mitosis as an anti-cancer drug target. Chromosoma, 2013, 122, 431-449.	1.0	47
50	A Transcriptional and Metabolic Signature of Primary Aneuploidy Is Present in Chromosomally Unstable Cancer Cells and Informs Clinical Prognosis. Cancer Research, 2013, 73, 6401-6412.	0.4	82
51	Molecular and cytogenetic changes in multi-drugÂresistant cancer cells and their influence on new compounds testing. Cancer Chemotherapy and Pharmacology, 2013, 72, 683-697.	1.1	25
52	Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor PrognosisÂof Lung Adenocarcinoma. Annals of Thoracic Surgery, 2013, 96, 1790-1794.	0.7	36
53	Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 2013, 13, 714-726.	12.8	3,667
54	Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacologica Sinica, 2013, 34, 541-548.	2.8	17
55	Genetic instability: tipping the balance. Oncogene, 2013, 32, 4459-4470.	2.6	81
56	2n or not 2n: Aneuploidy, polyploidy and chromosomal instability in primary and tumor cells. Seminars in Cell and Developmental Biology, 2013, 24, 370-379.	2.3	83

#	Article	IF	CITATIONS
57	Invited Commentary. Annals of Thoracic Surgery, 2013, 96, 1794-1795.	0.7	0
58	HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway. European Journal of Pharmacology, 2013, 720, 84-97.	1.7	8
59	Autophagy and cancer: taking the â€~toxic' out of cytotoxics. Journal of Pharmacy and Pharmacology, 2013, 65, 777-789.	1.2	18
60	The cancer biology of whole-chromosome instability. Oncogene, 2013, 32, 4727-4736.	2.6	106
61	High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecologic Oncology, 2013, 128, 500-505.	0.6	20
62	Taxane benefit in breast cancer—a role for grade and chromosomal stability. Nature Reviews Clinical Oncology, 2013, 10, 357-364.	12.5	48
63	Cancer heterogeneity: implications for targeted therapeutics. British Journal of Cancer, 2013, 108, 479-485.	2.9	753
64	Multi-Layered Cancer Chromosomal Instability Phenotype. Frontiers in Oncology, 2013, 3, 302.	1.3	32
65	A Double-Edged Sword: How Oncogenes and Tumor Suppressor Genes Can Contribute to Chromosomal Instability. Frontiers in Oncology, 2013, 3, 164.	1.3	56
66	Impact of chromosomal translocation and genomic instability on personalized medicine. Personalized Medicine, 2013, 10, 111-114.	0.8	0
67	The DN2 Myeloid-T (DN2mt) Progenitor is a Target Cell for Leukemic Transformation by the TLX1 Oncogene. Journal of Bone Marrow Research, 2013, 01, .	0.2	1
68	The Role of Chromosome Missegregation in Cancer Development: A Theoretical Approach Using Agent-Based Modelling. PLoS ONE, 2013, 8, e72206.	1.1	13
69	A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. PLoS ONE, 2013, 8, e66361.	1.1	41
70	Predicting Response to Preoperative Chemotherapy Agents by Identifying Drug Action on Modeled MicroRNA Regulation Networks. PLoS ONE, 2014, 9, e98140.	1.1	3
71	MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas. Oncogene, 2014, 33, 5511-5522.	2.6	66
72	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 2014, 12, e1001906.	2.6	185
73	Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN). Cell Cycle, 2014, 13, 2697-2706.	1.3	8
74	Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer, 2014, 14, 762.	1.1	16

#	Article	IF	CITATIONS
75	Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Research and Treatment, 2014, 144, 307-318.	1.1	18
76	Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology, 2014, 386, 101-120.	1.6	32
77	Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology, 2014, 8, 1095-1111.	2.1	347
78	Suppression of Genome Instability in pRB-Deficient Cells by Enhancement of Chromosome Cohesion. Molecular Cell, 2014, 53, 993-1004.	4.5	76
79	Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation. Oncogene, 2014, 33, 2487-2494.	2.6	41
81	Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therapeutic Advances in Gastroenterology, 2015, 8, 189-205.	1.4	8
82	Investigation of Epothilone B-Induced Cell Death Mechanisms in Human Epithelial Cancer Cells –in Consideration of Combined Treatment With Ionizing Radiation. Cancer Investigation, 2015, 33, 213-224.	0.6	6
83	Link between Aneuploidy and Chromosome Instability. International Review of Cell and Molecular Biology, 2015, 315, 299-317.	1.6	29
84	Advances in Laser Scanning Imaging Cytometry for High-Content Screening. Assay and Drug Development Technologies, 2015, 13, 66-78.	0.6	12
85	Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nature Reviews Genetics, 2015, 16, 459-471.	7.7	201
86	Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology, 2015, 26, 1340-1346.	0.6	61
87	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 2015, 9, 791-805.	2.1	27
88	HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. Journal of Neuro-Oncology, 2015, 122, 303-312.	1.4	36
89	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. Clinical Cancer Research, 2015, 21, 795-807.	3.2	89
90	Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Division, 2015, 10, 3.	1.1	202
91	Genetic Instability and Disease Prognostication. Recent Results in Cancer Research, 2015, 200, 81-94.	1.8	4
92	Caspase-2: the reinvented enzyme. Oncogene, 2015, 34, 1877-1882.	2.6	26
93	Chromosomal instability causes sensitivity to metabolic stress. Oncogene, 2015, 34, 4044-4055.	2.6	34

#	Article	IF	CITATIONS
94	Selective advantage of trisomic human cells cultured in non-standard conditions. Scientific Reports, 2016, 6, 22828.	1.6	90
95	Quantitative assessment of chromosome instability induced through chemical disruption of mitotic progression. Cell Cycle, 2016, 15, 1706-1714.	1.3	4
96	In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene, 2016, 35, 5446-5455.	2.6	51
97	Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. Neoplasia, 2016, 18, 387-397.	2.3	20
98	Difference Makers: Chromosomal Instability versus Aneuploidy in Cancer. Trends in Cancer, 2016, 2, 561-571.	3.8	60
99	Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. Molecular Cancer Therapeutics, 2016, 15, 2835-2844.	1.9	69
100	Cancer and Genomic Instability. , 2016, , 463-486.		1
101	Metabolism in Cancer. Recent Results in Cancer Research, 2016, , .	1.8	5
102	Metabolic Features of Cancer Treatment Resistance. Recent Results in Cancer Research, 2016, 207, 135-156.	1.8	34
103	Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. International Journal of Cancer, 2016, 139, 1546-1556.	2.3	23
105	Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. Physiological Reviews, 2016, 96, 1093-1126.	13.1	93
106	Genome Stability Requires p53. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026096.	2.9	101
107	Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Research, 2016, 24, 105-126.	1.0	59
108	Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. Molecular Oncology, 2016, 10, 179-193.	2.1	36
109	Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Research, 2016, 76, 902-911.	0.4	60
110	Consequences of aneuploidy in sickness and in health. Current Opinion in Cell Biology, 2016, 40, 41-46.	2.6	26
111	Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapy. Histochemistry and Cell Biology, 2016, 145, 497-508.	0.8	36
112	Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma. Clinical and Translational Oncology, 2016, 18, 632-640.	1.2	5

#	Article	IF	CITATIONS
113	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nature Communications, 2017, 8, 14093.	5.8	85
114	Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029611.	2.9	109
115	Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Human Cell, 2017, 30, 226-236.	1.2	7
116	Role of chromosomal instability in cancer progression. Endocrine-Related Cancer, 2017, 24, T23-T31.	1.6	67
117	Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. Cancer Research, 2017, 77, 5272-5286.	0.4	37
118	Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Seminars in Cancer Biology, 2017, 42, 13-19.	4.3	54
119	The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis. Biology, 2017, 6, 12.	1.3	118
120	Mechanisms of Chromosome Congression during Mitosis. Biology, 2017, 6, 13.	1.3	139
121	Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer. Cancers, 2017, 9, 151.	1.7	54
122	New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response. Genes, 2017, 8, 155.	1.0	30
124	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 4657-4664.	1.0	3
125	Cancer: a CINful evolution. Current Opinion in Cell Biology, 2018, 52, 136-144.	2.6	36
126	Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2018, 11, e000043.	1.6	159
127	Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Annals of Oncology, 2018, 29, 139-144.	0.6	39
128	Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. Genes Chromosomes and Cancer, 2018, 57, 28-34.	1.5	1
129	The Oncogenic Functions of MASTL Kinase. Frontiers in Cell and Developmental Biology, 2018, 6, 162.	1.8	26
130	The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment. Cell, 2018, 174, 1347-1360.	13.5	422
131	Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy. Cancer Research, 2018, 78, 6282-6296.	0.4	20

#	Article	IF	CITATIONS
132	Genomic Copy Number Alterations in Serous Ovarian Cancer. , 2018, , .		0
133	Human Artificial Chromosome with Regulated Centromere: A Tool for Genome and Cancer Studies. ACS Synthetic Biology, 2018, 7, 1974-1989.	1.9	26
134	The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers, 2018, 10, 4.	1.7	128
135	Hypoxia and Noncoding RNAs in Taxane Resistance. Trends in Pharmacological Sciences, 2018, 39, 695-709.	4.0	23
136	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 2019, 11, 1149.	1.7	9
137	The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis. Cancers, 2019, 11, 1083.	1.7	41
138	Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers. Molecular Diagnosis and Therapy, 2019, 23, 707-721.	1.6	14
139	When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers. Genes, 2019, 10, 551.	1.0	15
140	The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability. Cells, 2019, 8, 1228.	1.8	34
141	Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment. JCO Precision Oncology, 2019, 3, 1-11.	1.5	0
142	A novel assay to screen siRNA libraries identifies protein kinases required for chromosome transmission. Genome Research, 2019, 29, 1719-1732.	2.4	16
143	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
144	Aneuploidy drives lethal progression in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11390-11395.	3.3	101
145	Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia, 2019, 21, 363-375.	2.3	27
146	Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20, 404-416.	7.7	443
147	Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6975-6984.	3.3	37
148	Centromere 17 copy number gain reflects chromosomal instability in breast cancer. Scientific Reports, 2019, 9, 17968.	1.6	18
149	The diverse consequences of aneuploidy. Nature Cell Biology, 2019, 21, 54-62.	4.6	140

#	Article	IF	CITATIONS
150	Environmental stresses induce karyotypic instability in colorectal cancer cells. Molecular Biology of the Cell, 2019, 30, 42-55.	0.9	22
151	Human artificial chromosome (HAC) for measuring chromosome instability (CIN) and identification of genes required for proper chromosome transmission. Experimental Cell Research, 2020, 387, 111805.	1.2	8
152	TR1801â€ADC: a highly potent cMet antibody–drug conjugate with high activity in patientâ€derived xenograft models of solid tumors. Molecular Oncology, 2020, 14, 54-68.	2.1	39
153	Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. Cancer Biology and Medicine, 2020, 17, 970-985.	1.4	10
154	Integrating pathology, chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma. Cell and Bioscience, 2020, 10, 122.	2.1	8
155	Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 4892-4903.	0.4	26
156	Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 4606-4615.	3.2	9
157	Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. Molecular Therapy - Oncolytics, 2020, 17, 562-570.	2.0	36
158	LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance. Cancer Research, 2020, 80, 1693-1706.	0.4	22
159	Chromosome Instability; Implications in Cancer Development, Progression, and Clinical Outcomes. Cancers, 2020, 12, 824.	1.7	38
160	Cancer and genomic instability. , 2021, , 495-519.		1
161	Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers. Experimental Biology and Medicine, 2021, 246, 1036-1044.	1.1	5
162	Reduced USP22 Expression Impairs Mitotic Removal of H2B Monoubiquitination, Alters Chromatin Compaction and Induces Chromosome Instability That May Promote Oncogenesis. Cancers, 2021, 13, 1043.	1.7	8
164	TGFBI is involved in the formation of polyploid cancer cells and the response to paclitaxel. Annals of Translational Medicine, 2021, 9, 693-693.	0.7	1
165	Impaired Expression of Cytoplasmic Actins Leads to Chromosomal Instability of MDA-MB-231 Basal-Like Mammary Gland Cancer Cell Line. Molecules, 2021, 26, 2151.	1.7	1
167	Up to your NEK2 in CIN. Oncotarget, 2021, 12, 723-725.	0.8	Ο
168	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	3.2	21
169	Karyotype Aberrations in Action: The Evolution of Cancer Genomes and the Tumor Microenvironment. Genes, 2021, 12, 558.	1.0	13

		FORT	
#	Article	IF	CITATIONS
170	Deep learning predicts chromosomal instability from histopathology images. IScience, 2021, 24, 102394.	1.9	29
172	Suv420 enrichment at the centromere limits Aurora B localization and function. Journal of Cell Science, 2021, 134, .	1.2	7
174	Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 2022, 23, 74-88.	16.1	499
175	Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Developmental Cell, 2021, 56, 2427-2439.e4.	3.1	101
176	PROBING BREAST CANCER THERAPEUTIC RESPONSES BY DNA CONTENT PROFILING. International Journal of Medicine and Medical Research, 2019, 5, 47-57.	0.0	2
177	The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genetics, 2017, 13, e1006707.	1.5	36
178	The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. PLoS ONE, 2013, 8, e56707.	1.1	28
179	Tumor suppressor protein p53-mediated repression of human mitotic centromere-associated kinesin gene expression is exerted via down-regulation of Sp1 level. PLoS ONE, 2017, 12, e0189698.	1.1	5
180	Usp7 protects genomic stability by regulating Bub3. Oncotarget, 2014, 5, 3728-3742.	0.8	21
181	Chromosomal instability and acquired drug resistance in multiple myeloma. Oncotarget, 2017, 8, 78234-78244.	0.8	21
182	NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget, 2014, 5, 11986-11997.	0.8	54
183	A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Oncotarget, 2015, 6, 41383-41397.	0.8	33
184	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. Oncotarget, 2015, 6, 31693-31701.	0.8	6
185	Chromosomal instability triggers cell death via local signalling through the innate immune receptor Toll. Oncotarget, 2015, 6, 38552-38565.	0.8	18
186	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. Oncotarget, 2016, 7, 885-901.	0.8	31
187	Development of a novel HAC-based "gain of signal―quantitative assay for measuring chromosome instability (CIN) in cancer cells. Oncotarget, 2016, 7, 14841-14856.	0.8	25
188	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget, 2016, 7, 49099-49106.	0.8	2
189	Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells. Current Drug Targets, 2010, 11, 1341-1350.	1.0	40

	CHATON	I KEPOKI	
#	Article	IF	CITATIONS
190	Biomarkers for Systemic Therapy in Ovarian Cancer. Current Cancer Drug Targets, 2014, 14, 259-273.	0.8	6
191	Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory. Biopolymers and Cell, 2012, 28, 267-280.	0.1	23
192	Centrosome Aberrations as Drivers of Chromosomal Instability in Breast Cancer. Endocrinology, 2021, 162, .	1.4	8
193	Precision diagnostics: Integration of tissue pathology and genomics in cancer. Pathology, 2021, 53, 809-817.	0.3	2
194	Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 323.	3.5	12
195	New Insights into Tubulin Binders. , 2011, , 259-278.		1
196	The prognostic and predictive value of gene expression signatures in breast cancer. , 2011, , 4-12.		0
197	Chemotherapy and metastatic breast cancer. , 2011, , 67-92.		0
198	Heterogeneity of Cancers and Its Implication for Targeted Drug Delivery. , 2013, , 337-362.		0
199	Cabazitaxel for the Treatment of Prostate Cancer. , 2016, , 187-214.		0
200	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
203	Cell-Cell Fusion Mediated by Viruses and HERV-Derived Fusogens in Cancer Initiation and Progression. Cancers, 2021, 13, 5363.	1.7	19
207	CINSARC: a new look into an old concept gives hope for new treatments for synovial sarcomas. Translational Pediatrics, 2013, 2, 70-2.	0.5	1
208	Upregulation of colonic and hepatic tumor overexpressed gene is significantly associated with the unfavorable prognosis marker of human hepatocellular carcinoma. American Journal of Cancer Research, 2016, 6, 690-700.	1.4	3
209	Papel de la activación adicional del gen RA en el desarrollo del fenotipo resistente a la castración en el cáncer de próstata. Actas Urológicas Españolas, 2021, 46, 78-78.	0.3	0
210	Additional activation of the AR gene may be involved in the development of the castration resistance phenotype in prostate cancer. Actas Urológicas Españolas (English Edition), 2022, , .	0.2	0
211	Quantifying chromosomal instability from intratumoral karyotype diversity using agent-based modeling and Bayesian inference. ELife, 2022, 11, .	2.8	14
216	Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. Journal of Breast Cancer, 2022, 25, 178.	0.8	3

#	Article	IF	CITATIONS
217	Overexpression of satellite RNAs in heterochromatin induces chromosomal instability and reflects drug sensitivity in mouse cancer cells. Scientific Reports, 2022, 12, .	1.6	1
218	The impact of monosomies, trisomies and segmental aneuploidies on chromosomal stability. PLoS ONE, 2022, 17, e0268579.	1.1	11
219	Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers. Cell Death and Differentiation, 2023, 30, 37-53.	5.0	4
220	Suppression of Chromosome Instability Limits Acquired Drug Resistance. Molecular Cancer Therapeutics, 2022, 21, 1583-1593.	1.9	1
222	Inhibition of insulinâ€like growth factorâ€1 receptor enhances eribulinâ€induced <scp>DNA</scp> damage in colorectal cancer. Cancer Science, 2022, 113, 4207-4218.	1.7	2
223	A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. Npj Precision Oncology, 2022, 6, .	2.3	3
224	Suppression of chromosome instability by targeting a DNA helicase in budding yeast. Molecular Biology of the Cell, 2023, 34, .	0.9	1
225	Generation of aneuploid cells and assessment of their ability to survive in presence of chemotherapeutic agents. Methods in Cell Biology, 2024, , 21-33.	0.5	0
226	Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration. Frontiers in Immunology, 0, 13, .	2.2	2
227	Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma. Biochemical Pharmacology, 2023, 208, 115408.	2.0	4
228	Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Breast Cancer: Targets and Therapy, 0, Volume 15, 189-211.	1.0	0
229	Mechanisms of chromosomal instability (CIN) tolerance in aggressive tumors: surviving the genomic chaos. Chromosome Research, 2023, 31, .	1.0	4
230	Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Reports Medicine, 2023, 4, 100937.	3.3	11
231	The progress in our understanding of CIN in breast cancer research. Frontiers in Oncology, 0, 13, .	1.3	1
232	Deep learning in digital pathology for personalized treatment plans of cancer patients. Seminars in Diagnostic Pathology, 2023, 40, 109-119.	1.0	4
233	cGAS–STING signalling in cancer: striking a balance with chromosomal instability. Biochemical Society Transactions, 2023, 51, 539-555.	1.6	10
236	Implications of Chemokine Heterogenicity in Cancer Metastasis. , 2023, , 115-136.		1
238	Chromosome instability and aneuploidy in the mammalian brain. Chromosome Research, 2023, 31, .	1.0	1

#	Article	IF	CITATIONS
240	The yin and yang of chromosomal instability in prostate cancer. Nature Reviews Urology, 0, , .	1.9	0